NCT05769920View on ClinicalTrials.gov

Dose Escalation TTHX1114 Ophthalmic Solution

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions

Corneal Epithelial Degeneration

Interventions

DRUG

TTHX1114(NM141) Ophthalmic Solution

Eye drop twice daily

Trial Locations (1)

90630

Trefoil Clinical Site #132, Cypress

All Listed Sponsors

lead

Trefoil Therapeutics, Inc.

INDUSTRY